WO2007065017A2 - Systeme d'administration de liposomes cationiques a oligonucleotides - Google Patents

Systeme d'administration de liposomes cationiques a oligonucleotides Download PDF

Info

Publication number
WO2007065017A2
WO2007065017A2 PCT/US2006/046298 US2006046298W WO2007065017A2 WO 2007065017 A2 WO2007065017 A2 WO 2007065017A2 US 2006046298 W US2006046298 W US 2006046298W WO 2007065017 A2 WO2007065017 A2 WO 2007065017A2
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
oligomer
seq
cholesterol
acid
Prior art date
Application number
PCT/US2006/046298
Other languages
English (en)
Other versions
WO2007065017A3 (fr
Inventor
Neal Clifford Goodwin
Viktor Peykov
Wendi Rodrigueza
Sydney Ugwu
Tong Xuan
Original Assignee
Pronai Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronai Therapeutics, Inc. filed Critical Pronai Therapeutics, Inc.
Publication of WO2007065017A2 publication Critical patent/WO2007065017A2/fr
Publication of WO2007065017A3 publication Critical patent/WO2007065017A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Abstract

Cette invention concerne des compositions et des méthodes visant à inhiber l'expression génique. Cette invention concerne en particulier des oligonucléotides séquestrés dans des liposomes cationiques servant au traitement du cancer.
PCT/US2006/046298 2005-12-01 2006-12-01 Systeme d'administration de liposomes cationiques a oligonucleotides WO2007065017A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US74123105P 2005-12-01 2005-12-01
US74122705P 2005-12-01 2005-12-01
US60/741,227 2005-12-01
US60/741,231 2005-12-01
US77830506P 2006-03-02 2006-03-02
US77831506P 2006-03-02 2006-03-02
US60/778,315 2006-03-02
US60/778,305 2006-03-02

Publications (2)

Publication Number Publication Date
WO2007065017A2 true WO2007065017A2 (fr) 2007-06-07
WO2007065017A3 WO2007065017A3 (fr) 2007-09-20

Family

ID=38092900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046298 WO2007065017A2 (fr) 2005-12-01 2006-12-01 Systeme d'administration de liposomes cationiques a oligonucleotides

Country Status (1)

Country Link
WO (1) WO2007065017A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367628B2 (en) 2005-12-01 2013-02-05 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
WO2021055660A1 (fr) * 2019-09-18 2021-03-25 The Regents Of The University Of California Nanoliposomes produisant des protéines et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014172A1 (fr) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition de l'expression de la proteine bcl-2 par des nucleotides olidodesoxy antisens se presentant sous forme de liposomes
WO2002092617A1 (fr) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Approche combinee du traitement du cancer au moyen d'un oligomere antisens de c-myc
WO2004035523A1 (fr) * 2002-10-16 2004-04-29 Neopharm, Inc. Analogues de cardiolipine cationiques et utilisation de ceux-ci
WO2005067632A2 (fr) * 2004-01-07 2005-07-28 Neopharm, Inc. Compositions lipidiques et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014172A1 (fr) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition de l'expression de la proteine bcl-2 par des nucleotides olidodesoxy antisens se presentant sous forme de liposomes
WO2002092617A1 (fr) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Approche combinee du traitement du cancer au moyen d'un oligomere antisens de c-myc
WO2004035523A1 (fr) * 2002-10-16 2004-04-29 Neopharm, Inc. Analogues de cardiolipine cationiques et utilisation de ceux-ci
WO2005067632A2 (fr) * 2004-01-07 2005-07-28 Neopharm, Inc. Compositions lipidiques et leurs utilisations

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US9393258B2 (en) 2004-06-01 2016-07-19 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US8367628B2 (en) 2005-12-01 2013-02-05 Pronai Therapeutics, Inc. Amphoteric liposome formulation
WO2021055660A1 (fr) * 2019-09-18 2021-03-25 The Regents Of The University Of California Nanoliposomes produisant des protéines et leurs utilisations

Also Published As

Publication number Publication date
WO2007065017A3 (fr) 2007-09-20

Similar Documents

Publication Publication Date Title
EP1971371B1 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
CA2631677C (fr) Formulation de liposomes amphoteres
WO2014071379A1 (fr) Détermination de dose et administration de thérapies anticancéreuses oligonucléotidiques
KR101839864B1 (ko) 암을 치료하는 방법
WO2017192470A1 (fr) Polythérapie d'anticorps anti-il-10 et de compositions comprenant des nanoparticules lipidiques et des oligonucléotides cpg agonistes de tlr9
JP5199666B2 (ja) 白血病を治療するための組成物および方法
WO2014071406A1 (fr) Méthodes d'utilisation de biomarqueurs pour le traitement du cancer par modulation de l'expression de bcl2
WO2009051712A1 (fr) Formulation liposomiale amphotère d'adni
JPWO2020056304A5 (fr)
WO2007065017A2 (fr) Systeme d'administration de liposomes cationiques a oligonucleotides
WO2007064853A2 (fr) Oligonucleotides d'acide nucleique bloque
JP5615509B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
WO2022232652A1 (fr) Compositions de fluorocarbone et procédés d'amélioration de l'immunothérapie
WO2019132021A1 (fr) Composition pharmaceutique
AU2013337298A1 (en) Dosing and administration of oligonucleotide cancer therapies
TW202402305A (zh) 癌症治療之免疫增強
AU2013337251A1 (en) Methods of using biomarkers for the treatment of cancer by modulation of BCL2|expression
JP2015017112A (ja) フコシル化糖鎖産生細胞用物質送達担体

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06838962

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06838962

Country of ref document: EP

Kind code of ref document: A2